Drugs / alpha fetoprotein plasmid DNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00093548 | — | liver cancer | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alpha fetoprotein plasmid DNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00093548 ↗ |
| Modality | Vaccine | “full length AFP in a plasmid DNA construct in combination with an AFP-expressing replication-deficient adenovirus (AdV) in a prime-boost vaccine strategy” PMID 24708667 ↗ Apr 2014 |
| Route | Intramuscular | “Patients receive vaccination comprising AFP plasmid DNA and sargramostim (GM-CSF) plasmid DNA intramuscularly (IM) on days 1, 30, and 60” NCT00093548 ↗ |